Drugs / LZM012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06110676 | Aug 2023 → Apr 2025 | psoriasis | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LZM012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06110676 ↗ |
| Action | Inhibit | “Recombinant anti-human IL-17A/F humanized monoclonal antibody injection” NCT06110676 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-human IL-17A/F humanized monoclonal antibody injection” NCT06110676 ↗ |